Volume 18, Issue 2

Volume 18, Issue 2
15June2023

Letter from the ECCO President

Britta Siegmund, ECCO President


Britta Siegmund
© ECCO

 

Dear ECCO Friends,

As winter has turned first into spring and then into summer, a lot of activities have been taking place within ECCO and it is therefore good to have a new issue of ECCO News to keep ECCO Members up to date with the latest developments.

We have all been waiting for the update of the Guideline on Extraintestinal Manifestations in IBD. In this issue of ECCO News, Torsten Kucharzik, as GuiCom Chair, provides an executive summary that will potentially stimulate all readers to go immediately to the recently published guideline. Another highlight relating to ECCO Publications is the summary of the Topical Review on Multidisciplinary Perinatal Care in IBD, presented by Lihi Godny, who coordinated this together with Catherine Wall as a D-ECCO Initiative. Thanks to all the authors for filling this important gap!

Posted in ECCO News, Letters from the ECCO President, Volume 18, Issue 2

15June2023

Call for abstracts for the 19th Congress of ECCO

ABSTRACT SUBMISSION OPEN NOW



To submit an abstract for the 19th Congress of ECCO, use our ECCO Portal.

Please also view important information on the submission process and the guidelines for abstract submission.

Posted in ECCO News, Congress News, Volume 18, Issue 2

15June2023

ECCO'24 - Preliminary Scientific and Educational Programmes



The Educational Programme of the 19th Congress of ECCO starts prior to the official start of the ECCO Congress and courses take place from February 21-24, 2024. These activities target ECCO’s different interest groups including young gastroenterologists, surgeons, paediatricians, pathologists, IBD Nurses, dietitians, allied health professionals and scientists.

Posted in ECCO News, Congress News, Volume 18, Issue 2

15June2023

Call for Participants: The 15th N-ECCO School


N-ECCO School
© ECCO

At the 19th Congress of ECCO in Stockholm, the Nurses of ECCO (N-ECCO) will host the educational activity for IBD Nurses, N-ECCO School, for the 15th time. ECCO intends to give nurses, who might be still in training and have an interest in IBD, the possibility to attend an IBD-focused course. The ultimate aim of this programme is to improve nurse education throughout Europe.

Posted in ECCO News, Congress News, Volume 18, Issue 2, N-ECCO

15June2023

Call for Participants: The 22nd IBD Intensive Course for Trainees


IBD Intensive Course for Trainees
© ECCO

The 22nd ECCO IBD Intensive Course for Trainees designed for residents, fellows in gastroenterology and junior faculty will take place in Stockholm, Sweden, on February 21, 2024, immediately prior to our next Congress. We are pleased to inform you that the preliminary programme for this course is already available.

Posted in ECCO News, EduCom, Congress News, Volume 18, Issue 2

15June2023

SciCom F&G: Continuous Growth and New Developments


Travel awards ECCO'23
© ECCO

This year, available funding for ECCO Fellowships and Grants Programme (F&G) increased to 1.9 Million Euros for this year’s Call 2023 (to be awarded ECCO’24), this is the largest funding volume to date. With diverse funding streams for innovative research and international collaborations such as the Pioneer Award and the new Global Grant as well as those specifically for early career scientists, Dieticians and Nurses, the ECCO F&G Programme has really grown in the last five years.

Posted in ECCO News, SciCom, Committee News, Volume 18, Issue 2

15June2023

ECCO Pioneer Award Synopsis: Daniel Kotlarz

Daniel Kotlarz, ECCO Grant Awardee

Decoding molecular mechanisms and druggable targets of VEO-IBD by multimodal single-cell profiling


Daniel Kotlarz
© Daniel Kotlarz

Objectives

The pathogenesis and course of Inflammatory Bowel Disease (IBD) are heterogeneous and have striking age-dependent characteristics. In particular, children with very early-onset IBD (VEO-IBD) show a higher incidence of unclassified IBD and develop courses different from adult-onset forms. VEO-IBD is a rare condition, but the incidence is increasing globally at an alarming pace. Notably, VEO-IBD patients often fail to respond to conventional therapies and show life-threatening conditions.

In paradigmatic studies, we have previously reported IL-10R deficiencies as a monogenic cause in children with intractable VEO-IBD. Based on knowledge of the molecular disease mechanisms, IL-10R-deficient patients could be cured by allogeneic haematopoietic stem cell transplantation. This prime example of translational research has shifted paradigms by demonstrating the relevance of genetics for the treatment of VEO-IBD patients. Our genetic screen of one of the largest international VEO-IBD cohorts has revealed disease-causing mutations in approximately 20% of analysed patients (>60 genetic entities) and suggested optimised treatment for a significant number of children. However, most VEO IBD patients still lack definitive diagnosis and the disease mechanisms remain largely elusive.

Posted in ECCO News, SciCom, Committee News, Volume 18, Issue 2, Fellowships & Grants Synopsis Reports

15June2023

ECCO Pioneer Award Synopsis: Marieke Barnhoorn and Gianluca Matteoli as co-partner in Leuven

Marieke Barnhoorn, ECCO Grant Awardee and Gianluca Matteoli as co-partner in Leuven

Unraveling the role of fibroblast subsets in fibrostenotic Crohn’s disease


Andrea van der Meulen-de Jong, Marieke Barnhoorn, Luuk Hawinkels, Gianluca Matteoli
© Marieke Barnhoorn

Objectives

Fibrosis occurs in most Crohn’s Disease (CD) patients, although it only becomes clinically apparent in those who develop stenotic disease. Fibroblasts are considered the main cell type contributing to fibrosis by production and remodelling of the extracellular matrix. Recently, changes have been shown in the relative abundance of different fibroblast subsets in the inflamed intestine of IBD patients. However, the abundance of fibroblast subsets and their spatial localisation in fibrostenotic IBD tissue are currently unknown. The overall aim of this project is to unravel the role of fibroblast subsets in the pathogenesis of fibrostenotic CD and to identify novel therapeutic targets.

As a first objective, we will map the differences in abundance and spatial distribution of fibroblast subsets in patients with inflammatory and stenotic CD using a unique 40-marker fibroblast Imaging Mass Cytometry (IMC) antibody panel. Thereafter, as a second objective, we will investigate (pathogenic) fibroblast subsets derived from fibrostenotic lesions in CD patients using a fibroblast-rich, three-dimensional organoid-based model. Lastly, we will assess in CD patients the effects of Janus kinase (JAK) inhibition on the relative abundance of identified fibroblast subsets.

Posted in ECCO News, SciCom, Committee News, Volume 18, Issue 2, Fellowships & Grants Synopsis Reports

15June2023

ECCO Fellowship Study Synopsis: Brecht Hens

Brecht Hens, ECCO Grant Awardee

Circulating tumour DNA and artificial intelligence as screening tools for dysplasia in Inflammatory Bowel Disease


Brecht Hens
© Brecht Hens

Background & aim of research

Patients with colonic Inflammatory Bowel Disease (IBD) are at increased risk for the development of colorectal cancer. Surveillance colonoscopy is therefore advised, starting at 8 years after initial diagnosis of IBD and then repeated every 1–5 years based on the individual risk profile. However, screening based solely on colonoscopy is flawed as interval carcinomas still account for around 40%–50% of all colitis-associated carcinomas (CAC). In sporadic colorectal cancer, both liquid biopsies and artificial intelligence (AI) have proved to be feasible and to yield promising results. Patients with IBD were systemically excluded from these trials.

The aim of this research project is to improve the early detection of IBD-associated dysplasia by (1) developing non-invasive biomarkers using blood and/or stool samples to identify high-risk individuals and (2) developing a machine learning algorithm to aid in the detection of neoplastic lesions during colonoscopy.

Posted in ECCO News, SciCom, Committee News, Volume 18, Issue 2, Fellowships & Grants Synopsis Reports

15June2023

Best Investigator-Initiated Study Award at ECCO'23

Maria Chaparro, ClinCom Member


Maria Chaparro
© ECCO

The study entitled "Withdrawal of anti-tumour necrosis factor in Inflammatory Bowel Disease patients in remission: a randomised placebo-controlled clinical trial" received one of the two Best Investigator-Initiated Study Award at ECCO’23.

Biologic anti-TNF drugs have been a game changer for patients with Inflammatory Bowel Disease. However, long-term maintenance of these drugs may be associated with potential adverse events and high costs. Therefore, patients and physicians are wondering whether it is possible to discontinue these drugs without significantly increasing the risk of recurrence.

Posted in ECCO News, Committee News, ECCO'23, ClinCom, Volume 18, Issue 2